Insights into drug discovery from natural products through structural modification

Fitoterapia

Volumn 103, Issue , 2015, Pages 231-241

  Chen, Jichao ^a   Li, Wenlong ^a   Yao, Hequan ^a   Xu, Jinyi ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Druggability; Natural products; Structural modification

Indexed keywords

4 PHENYLPIPERIDINE DERIVATIVE; ANALGESIC AGENT; ARTEMISININ DERIVATIVE; BENZOMORPHAN; BOTTROMYCIN A2; CAMPTOTHECIN; COMBRETASTATIN A4; CURCUMIN; CYCLOSPORIN A; EPOTHILONE B; EXATECAN; HALICHONDRIN B; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; ISP 1; LARGAZOLE; LIPHAGAL; LIPOXIN A; METHADONE; MORPHINANE DERIVATIVE; MORPHINE; NATURAL PRODUCT; OLEANOLIC ACID; ORIDONIN; PACLITAXEL; PHLORIZIN; POLYPEPTIDE ANTIBIOTIC AGENT; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; BIOLOGICAL PRODUCT; PRODRUG;

ARTICLE; BLOOD BRAIN BARRIER; CHEMICAL MODIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; MEDICINAL CHEMISTRY; METABOLIC STABILITY; NONHUMAN; PATENT; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHYSICAL CHEMISTRY; PLASMA; PRIORITY JOURNAL; PROCESS OPTIMIZATION; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN;

BIOLOGICAL PRODUCTS; DRUG DESIGN; DRUG STABILITY; MOLECULAR STRUCTURE; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84928801703     PISSN: 0367326X     EISSN: 18736971     Source Type: Journal    
DOI: 10.1016/j.fitote.2015.04.012     Document Type: Review

References (145)

1. D.D. Baker, M. Chu, U. Oza, and V. Rajgarhia The value of natural products to future pharmaceutical discovery Nat Prod Rep 24 2007 1225 1244
2. G.M. Cragg, and D.J. Newman Natural products: a continuing source of novel drug leads Biochim Biophys Acta 2013 1830 3670 3695
3. D.J. Newman, and G.M. Cragg Natural products as sources of new drugs over the 30 years from 1981 to 2010 J Nat Prod 75 2012 311 335
4. B.B. Mishra, and V.K. Tiwari Natural products: an evolving role in future drug discovery Eur J Med Chem 46 2011 4769 4807
5. W.R. Galloway, M. Diáz-Gavilán, A. Isidro-Llobet, and D.R. Spring Synthesis of unprecedented scaffold diversity Angew Chem Int Ed 48 2009 1194 1196
6. J. Clardy, and C. Walsh Lessons from natural molecules Nature 432 2004 829 837
7. M. Feher, and J.M. Schmidt Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry J Chem Inf Comput Sci 43 2003 218 227
8. T. Henkel, R.M. Brunne, H. Müller, and F. Reichel Statistical investigation into the structural complementarity of natural products and synthetic compounds Angew Chem Int Ed 38 1999 643 647
9. J. Rosén, J. Gottfries, S. Muresan, A. Backlund, and T.I. Oprea Novel chemical space exploration via natural products J Med Chem 52 2009 1953 1962
10. L. Eberhardt, K. Kumar, and H. Waldmann Exploring and exploiting biologically relevant chemical space Curr Drug Targets 12 2011 1531 1546
11. K. Grabowski, and G. Schneider Properties and architecture of drugs and natural products revisited Curr Chem Biol 1 2007 115 127
12. J. Hert, J.J. Irwin, C. Laggner, M.J. Keiser, and B.K. Shoichet Quantifying biogenic bias in screening libraries Nat Chem Biol 5 2009 479 483
13. G.M. Keseru, and G.M. Makara The influence of lead discovery strategies on the properties of drug candidates Nat Rev Drug Discov 8 2009 203 212
14. S. Dandapani, and L.A. Marcaurelle Grand challenge commentary: accessing new chemical space for 'undruggable' targets Nat Chem Biol 6 2010 861 863
15. R.J. Quinn, A.R. Carroll, N.B. Pham, P. Baron, M.E. Palframan, and L. Suraweera et al. Developing a druglike natural product library J Nat Prod 71 2008 464 468
16. R. Breinbauer, M. Manger, M. Scheck, and H. Waldmann Natural product guided compound library development Curr Med Chem 9 2002 2129 2145
17. K.C. Morrison, and P.J. Hergenrother Natural products as starting points for the synthesis of complex and diverse compounds Nat Prod Rep 31 2014 6 14
18. E.E. Carlson Natural products as chemical probes ACS Chem Biol 5 2010 639 653
19. F. von Nussbaum, M. Brands, B. Hinzen, S. Weigand, and D. Hbich Antibacterial natural products in medicinal chemistry - exodus or revival ? Angew Chem Int Ed 45 2006 5072 5129
20. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 64 2012 4 17
21. F.E. Koehn Biosynthetic medicinal chemistry of natural product drugs Med Chem Commun 3 2012 854 865
22. W. Curatolo Physical chemical properties of oral drug candidates in the discovery and exploratory development settings Pharm Sci Technol Today 1 1998 387 393
23. J.M. Liu, M.Y. Ni, Y.F. Fan, Y.Y. Tu, Z.H. Wu, and Y.L. Wu et al. The structure and reactions of arteannuin Acta Chim Sin 37 1979 129 141
24. S.Q. Zhu, W.H. Liu, X.X. Ke, J.F. Li, R.J. Hu, and H.J. Cui et al. Artemisinin reduces cell proliferation and induces apoptosis in neuroblastom Oncol Rep 32 2014 1094 1100
25. R. He, B.T. Mott, A.S. Rosenthal, D.T. Genna, G.H. Posner, and R. Arav-Boger An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities PLoS One 6 2011 e24334
26. A.J. Lin, D.L. Klayman, and W.K. Milhous Antimalarial activity of new water-soluble dihydroartemisinin derivatives J Med Chem 30 1987 2147 2150
27. Ying Li, Y.M. Zhu, H.J. Jiang, J.P. Pan, G.S. Wu, and J.M. Wu Synthesis and antimalarial activity of artemisinin derivatives containing an amino group J Med Chem 43 2000 1635 1640
28. R.K. Haynes, B. Fugmann, J. Stetter, K. Rieckmann, H.D. Heilmann, and H.W. Chan et al. Artemisone - a highly active antimalarial drug of the artemisinin class Angew Chem Int Ed 45 2006 2082 2088
29. E. Fujita, Y. Nagao, K. Kaneko, S. Nakazawa, and H. Kuroda The antitumor and antibacterial activity of the Isodon diterpenoids Chem Pharm Bull 24 1976 2118 2127
30. C.Y. Li, E.Q. Wang, Y. Cheng, and J.K. Bao Oridonin: an active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics Int J Biochem Cell Biol 43 2011 701 704
31. G. Zhou, H. Kang, L. Wang, L. Gao, P. Liu, and J. Xie et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo Blood 109 2007 3441 3450
32. F.J. Bohanon, X.F. Wang, C.Y. Ding, Y. Ding, G.L. Radhakrishnan, and C. Rastellini et al. Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis J Surg Res 190 2014 55 63
33. S.T. Xu, D.H. Li, L.L. Pei, H. Yao, C.Q. Wang, and H. Can et al. Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives Bioorg Med Chem Lett 24 2014 2811 2814
34. J.Y. Xu, J.Y. Yang, Q. Ran, L. Wang, J. Liu, and Z.X. Wang et al. Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates Bioorg Med Chem Lett 18 2008 4741 4744
35. C.Y. Ding, Y.S. Zhang, H.J. Chen, Z.D. Yang, C. Wild, and L.L. Chu et al. Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility J Med Chem 56 2013 5048 5058
36. M.E. Wall, M.C. Wani, C.E. Cook, K.H. Palmer, A.T. McPhail, and G.A. Sim Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate J Am Chem Soc 88 1966 3888 3890
37. N.H. Oberlies, and D.J. Kroll Camptothecin and taxol: historic achievements in natural products research J Nat Prod 67 2004 129 135
38. S.T. Liew, and L.X. Yang Design, synthesis and development of novel camptothecin drugs Curr Pharm Des 14 2008 1078 1097
39. J. Ohwada, S. Ozawa, M. Kohchi, H. Fukuda, C. Murasaki, and H. Suda et al. Synthesis and biological activities of a pH-dependently activated water-soluble prodrug of a novel hexacyclic camptothecin analog Bioorg Med Chem Lett 19 2009 2772 2776
40. Q.Y. Li, X.Q. Deng, Y.G. Zu, H.Y. Lv, L. Su, and L.P. Yao et al. Cytotoxicity and topo I targeting activity of substituted 10 - nitrogenous heterocyclic aromatic group derivatives of SN-38 Eur J Med Chem 45 2010 3200 3206
41. H. Lachance, S. Wetzel, K. Kumar, and H. Waldmann Charting, navigating, and populating natural product chemical space for drug discovery J Med Chem 55 2012 5989 6001
42. K. Taori, V.J. Paul, and H. Luesch Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am Chem Soc 130 2008 1806 1807
43. J.A. Souto, E. Vaz, I. Lepore, A.C. Poppler, G. Franci, and R. Alvarez et al. Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7-modified analogues J Med Chem 53 2010 4654 4667
44. A.A. Bowers, N. West, T.L. Newkirk, A.E. Troutman-Youngman, S.L. Schreiber, and O. Wiest et al. Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold Org Lett 11 2009 1301 1304
45. F. Chen, H. Chai, M.B. Su, Y.M. Zhang, J. Li, and X. Xie et al. Potent and orally efficacious bisthiazole-based histone deacetylase inhibitors ACS Med Chem Lett 5 2014 628 633
46. Y. Hirata, and D. Uemura Halichondrins - antitumor polyether macrolides from a marine sponge Pure Appl Chem 58 1986 701 710
47. D. Dabydeen, J.C. Burnett, R. Bai, P. Verdier-Pinard, S.J.H. Hickford, and G.R. Pettit et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin Mol Pharmacol 70 2006 1866 1875
48. B. Overmoyer Options for the treatment of patients with taxane-refractory metastatic breast cancer Clin Breast Cancer 8 2008 S61 S70
49. M.J. Yu, W. Zheng, B.M. Seletsky, B.A. Littlefield, and Y. Kishi Case history Annu Rep Med Chem 46 2011 227 241
50. B.M. Seletsky, Y. Wang, L.D. Hawkins, M.H. Palme, G.J. Habgood, and L.V. DiPietro et al. Structurally simplified macrolactone analogues of halichondrin B Bioorg Med Chem Lett 14 2004 5547 5550
51. W. Zheng, B.M. Seletsky, M.H. Palme, P.J. Lydon, L.A. Singer, and C.E. Chase et al. Macrocyclic ketone analogues of halichondrin B Bioorg Med Chem Lett 14 2004 5551 5554
52. P. Aftimos, and A. Awada Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next? Adv Ther 28 2011 973 985
53. T. Fujita, K. Inoue, S. Yamamoto, T. Ikumoto, S. Sasaki, and R. Toyama et al. S Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite J Antibiot 47 1994 208 215
54. C.R. Strader, C.J. Pearce, and N.H. Oberlies Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite J Nat Prod 74 2011 900 907
55. T. Fujita, M. Yoneta, R. Hirose, S. Sasaki, K. Inoue, and M. Kiuchi et al. Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity Bioorg Med Chem Lett 5 1995 847 852
56. T. Fujita, N. Hamamichi, M. Kiuchi, T. Matsuzaki, Y. Kitao, and K. Inoue et al. Determination of absolute configuration and biological activity of new immunosuppressants, mycestericins D, E, F and G J Antibiot 49 1996 846 853
57. H. Kataoka, K. Sugahara, K. Shimano, K. Teshima, M. Koyama, and A. Fukunari et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration Cell Mol Immunol 2 2005 439 448
58. D. Pelletier, and D.A. Hafler Fingolimod for multiple sclerosis N Engl J Med 366 2012 339 347
59. F. Marion, D.E. Williams, B.O. Patrick, I. Hollander, R. Mallon, and S.C. Kim et al. Liphagal, a selective inhibitor of PI3 kinaserisolated from the sponge aka coralliphaga: structure elucidation and biomimetic synthesis Org Lett 8 2006 321 324
60. A.R. Pereira, W.K. Strangman, F. Marion, L. Feldberg, D. Roll, and R. Mallon et al. Synthesis of phosphatidylinositol 3-kinase(PI3k)inhibitory analogues of the sponge meroterpenoid liphagal J Med Chem 53 2010 8523 8533
61. V.S. Govindarajan Turmeric - chemistry, technology, and quality Crit Rev Food Sci Nutr 12 1980 199 301
62. M. Salem, S. Rohani, and E.R. Gillies Curcumin, a promising anti-cancer therapeutic: a review of its chemical properties, bioactivity and approaches to cancer cell delivery RSC Adv 4 2014 10815 10829
63. M.A. Tomren, M. Masson, T. Loftsson, and H.H. Tonnesen Studies on curcumin and curcuminoids XXXI. Symmetric and asymmetric curcuminoids: stability, activity and complexation with cyclodextrin Int J Pharm 338 2007 27 34
64. M.H. Leung, and T.W. Kee Effective stabilization of curcumin by association to plasma proteins: human serum albumin and fibrinogen Langmuir 25 2009 5773 5777
65. Y.J. Wang, M.H. Pan, A.L. Cheng, L.I. Lin, Y.S. Ho, and C.Y. Hsieh et al. Stability of curcumin in buffer solutions and characterization of its degradation products Pharm Biomed Anal 15 1997 1867 1878
66. A. Simon, D.P. Allais, J.L. Duroux, J.P. Basly, S. Durand Fontanier, and C. Delage Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships Cancer Lett 129 1998 111 116
67. A.T. Dinkova-Kostova, and P. Talalay Relation of structure of curcumin analogs to their potencies as inducers of Phase 2 detoxification enzymes Carcinogenesis 20 1999 911 914
68. G. Liang, L.L. Shao, Y. Wang, C.G. Zhao, Y.H. Chu, and J. Xiao et al. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents Bioorg Med Chem 17 2009 2623 2631
69. L. Chen, S. Magesh, H. Wang, C.S. Yang, A.N.T. Kong, and L.Q. Hu Design and synthesis of novel iminothiazinylbutadienols and divinylpyrimidinethiones as ARE inducers Bioorg Med Chem 24 2014 940 943
70. S. Chakraborti, G. Dhar, V. Dwivedi, A. Das, A. Poddar, and G. Chakraborti et al. Stable and potent analogues derived from the modification of the dicarbonyl moiety of curcumin Biochemistry 52 2013 7449 7460
71. C.M. Lin, S.B. Singh, P.S. Chu, R.O. Dempcy, J.M. Schmidt, and G.R. Pettit et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study Mol Pharmacol 34 1988 200 208
72. G.R. Pettit, B.E. Toki, D.L. Herald, M.R. Boyd, E. Hamel, and R.K. Pettit et al. Antineoplastic agents. 410. Asymmetric hydroxylation of trans-combretastatin A-4 J Med Chem 42 1999 1459 1465
73. T. Pirali, S. Busacca, L. Beltrami, D. Imovilli, F. Pagliai, and G. Miglio et al. Synthesis and cytotoxic evaluation of combretafurans, potential scaffolds for dual-action antitumoral agents J Med Chem 49 2006 5372 5376
74. L. Cafici, T. Pirali, F. Condorelli, E. Del Grosso, A. Massarotti, and G. Sorba et al. Solution-phase parallel synthesis and biological evaluation of combretatriazoles J Comb Chem 10 2008 732 740
75. S.M. Nathwani, L. Hughes, L.M. Greene, M. Carr, N.M. O'Boyle, and S. McDonnell et al. Novel cis-restricted β-lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro Oncol Rep 29 2013 585 594
76. R. Alvarez, C. Alvarez, F. Mollinedo, B.G. Sierra, M. Medarde, and R. Peláez Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds Bioorg Med Chem 17 2009 6422 6431
77. J.P. Liou, J.Y. Chang, C.W. Chang, C.Y. Chang, N. Mahindroo, and F.M. Kuo et al. Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents J Med Chem 47 2004 2897 2905
78. E.G. Barbosa, L.A. Bega, A. Beatriz, T. Sarkar, E. Hamel, and M.S. do Amaral et al. A diaryl sulfide, sulfoxide, andsulfone bearing structural similarities to combretastatin A-4 Eur J Med Chem 44 2009 2685 2688
79. K. Gerth, N. Bedorf, G. Höfle, H. Irschik, and H. Reichenbach Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties J Antibiot 49 1996 560 563
80. R. Altaha, T. Fojo, E. Reed, and J. Abraham Epothilones: a novel class of non-taxane microtubule-stabilizing agents Curr Pharm Des 8 2002 1707 1712
81. F.Y. Lee, R. Borzilleri, C.R. Fairchild, A. Kamath, R. Smykla, and R. Kramer et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent Cancer Chemother Pharmacol 63 2008 157 166
82. A. Conlin, M. Fornier, C. Hudis, S. Kar, and P. Kirkpatrick Ixabepilone Nat Rev Drug Discov 6 2007 953 954
83. J.F. Deeken, J.L. Marshall, M.J. Pishvaian, J. Hwang, C.M. Ahlers, and P.L. Clemens et al. A phase I study of oral Ixabepilone in patients with advanced solid tumors Cancer Chemother Pharmacol 73 2014 1071 1078
84. B.G. Smaglo, and M.J. Pishvaian Profile and potential of Ixabepilone in the treatment of pancreatic cancer Drug Des Devel Ther 8 2014 923 930
85. J.M. Waisvisz, M.G. van der Hoeven, J. van Peppen, W.C.M. Zwennis, and I. Bottromycin A new sulfur-containing antibiotic J Am Chem Soc 79 1957 4520 4521
86. 2: a potent antibiotic against MRSA and VRE Angew Chem Int Ed 48 2009 914 917
87. K. Kobayashi, M. Ichioka, T. Hirose, K. Nagai, A. Matsumoto, and H. Matsui et al. Bottromycin derivatives: efficient chemical modifications of the ester moiety and evaluation of anti-MRSA and anti-VRE activities Bioorg Med Chem Lett 20 2010 6116 6120
88. T.G. Burke, and Z. Mi Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin J Med Chem 36 1993 2580 2582
89. T.G. Burke, and Z. Mi The structural basis of camptothecin interactions with human serum albumin: impact on drug stability J Med Chem 37 1994 40 46
90. C. Bailly Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs Crit Rev Oncol Hematol 45 2003 91 108
91. P. Hautefaye, B. Cimetière, A. Pierré, S. Léonce, J. Hickman, and W. Laine et al. Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin Bioorg Med Chem Lett 13 2003 2731 2735
92. Z.Y. Miao, L.J. Zhu, G.Q. Dong, C.L. Zhuang, Y.L. Wu, and S.Z. Wang et al. A new strategy to improve the metabolic stability of lactone: discovery of (20S, 21S) -21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors J Med Chem 56 2013 7902 7910
93. C.N. Serhan Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and proresolution Prostaglandins Other Lipid Mediat 68-69 2002 433 455
94. B.D. Levy, and C.N. Serhan Exploring new approaches to the treatment of asthma: potential roles for lipoxins and aspirintriggered lipid mediators Drugs Today (Barc) 39 2003 373 384
95. N. Chiang, M. Arita, and C.N. Serhan Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX Prostaglandins Leukot Essent Fatty Acids 73 2005 163 177
96. 4 metabolic inactivation: 15-oxaprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase is a multifunctional eicosanoid oxidoreductase J Biol Chem 275 2000 25372 25380
97. 4 Bioorg Med Chem Lett 13 2003 3223 3226
98. C.B. Clish, J.A. O'Brien, K. Gronert, G.L. Stahl, N.A. Petasis, and C.N. Serhan Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo Proc Natl Acad Sci U S A 96 1999 8247 8252
99. 4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo J Med Chem 47 2004 2157 2165
100. 4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism FASEB J 21 2007 3877 3884
101. C. Petersen Analyse des Phloridzins Ann Acad Sci Fr 15 1835 178
102. J.R.L. Ehrenkranz, N.G. Lewis, C.R. Kahn, and J. Roth Phlorizin: a review Diabetes Metab Res Rev 21 2005 31 38
103. K. Tsujihara, M. Hongu, K. Saito, H. Kawanishi, K. Kuriyama, and M. Matsumotu et al. Na(+)-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives substituted on the B ring J Med Chem 42 1999 5311 5324
104. K. Katsuno, Y. Fujimori, Y. Takemura, M. Hiratochi, F. Itoh, and Y. Komatsu et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level J Pharmacol Exp Ther 320 2007 323 330
105. M. Isaji Bone: from a reservoir of minerals to a regulator of energy metabolism Kidney Int Suppl 79 2011 S14 S19
106. M. Meng, B.A. Ellsworth, A.A. Nirschl, P.J. McCann, M. Patel, and R.N. Girotra et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes J Med Chem 51 2008 1145 1149
107. S. Nomura, S. Sakamaki, M. Hongu, E. Kawanishi, Y. Koga, and T. Sakamoto et al. Discovery of canagliflozin, a novel Cglucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus J Med Chem 53 2010 6355 6360
108. M.A. Jordan Mechanism of action of antitumor drugs that interact with microtubules and tubulin Curr. Med. Chem. Anticancer Agents 2 2002 1 7
109. E.M. Kemper, A.E. van Zandbergen, C. Cleypool, H.A. Mos, W. Boogerd, and J.H. Beijnen et al. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein Clin Cancer Res 9 2003 2849 2855
110. H. Fischer, R. Gottschlich, and A. Seelig Blood-brain barrier permeation: molecular parameters governing passive diffusion J Membr Biol 165 1998 201 211
111. R. Antonie, Y.B. Liu, M.L. Michaelis, R.H. Himes, G.I. Georg, and K.L. Audus Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ J Med Chem 48 2005 832 838
112. M.A. Findeis, F. Schroeder, T.D. McKee, D. Yager, P.C. Fraering, and S.P. Creaser et al. Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa ACS Chem Neurosci 3 2012 941 951
113. N.O. Fuller, J.L. Hubbs, W.F. Austin, S.F. Creaser, T.D. McKee, and R.M.B. Loureiro et al. Initial optimization of a new series of γ secretase modulators derived from a triterpene glycoside ACS Med Chem Lett 3 2012 908 913
114. J.L. Hubbs, N.O. Fuller, W.F. Austin, R.C. Shen, S.P. Creaser, and T.D. McKee et al. Optimization of a natural product-based class of γ secretase modulators J Med Chem 55 2012 9270 9282
115. H. Qian, W.L. Huang, X.M. Wu, H.B. Zhang, J.P. Zhou, and W.C. Ye A new isochroman-4-one derivative from the peel of Musa sapientum L. and its total synthesis Chin Chem Lett 18 2007 1227 1230
116. J. Liu, H. Ren, J.Y. Xu, R.R. Bai, Q. Yan, and W.L. Huang et al. Total synthesis and antihypertensive activity of (+/-)7,8-dihydroxy-3-methyl-isochromanone-4 Bioorg Med Chem Lett 19 2009 1822 1824
117. R.R. Bai, X. Yang, Y. Zhu, Z.W. Zhou, W.J. Xie, and H.Q. Yao et al. Novel nitric oxide-releasing isochroman-4-one derivatives: synthesis and evaluation of antihypertensive activity Bioorg Med Chem 20 2012 6848 6855
118. R.R. Bai, X.J. Huang, X. Yang, W. Hong, Y.Q. Tang, and H.Q. Yao et al. Novel hybrids of natural isochroman-4-one bearing N-substituted isopropanolamine as potential antihypertensive candidates Bioorg Med Chem 21 2013 2495 2502
119. S.T. Xu, L.L. Pei, C.Q. Wang, Y.K. Zhang, D.H. Li, and H.Q. Yao et al. Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates ACS Med Chem Lett 5 2014 797 802
120. S.J. Tsai, and M.C. Yin Anti-oxidative, anti-glycative and antiapoptotic effects of oleanolic acid in brain of mice treated by dgalactose Eur J Pharmacol 689 2012 81 88
121. L. Fang, M. Wang, S.H. Gou, X.Y. Liu, H. Zhang, and F. Cao Combination of amino acid/dipeptide with nitric oxide donating oleanolic acid derivatives as Pept1 targeting antitumor prodrugs J Med Chem 57 2014 1116 1120
122. 2 (2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione s-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability J Med Chem 56 2013 4641 4655
123. C. Vézina, A. Kudelski, and S.N. Sehgal Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle J Antibiot 28 1975 721 726
124. S.R. Park, Y.J. Yoo, Y.H. Ban, and Y.J. Yoon Biosynthesis of rapamycin and its regulation: past achievements and recent progress J Antibiot 63 2010 434 441
125. J.P. Boni, B. Hug, C. Leister, and D. Sonnichsen Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations Semin Oncol 36 2009 S18 S25
126. W.W. Ma, and A. Jimeno Temsirolimus Drugs Today (Barc) 43 2007 659 669
127. B. Rini, S. Kar, and P. Kirkpatrick Temsirolimus Nat Rev Drug Discov 6 2007 599 600
128. Chinese Pharmacopeia Committee Pharmacopeia of People's Republic of China, 1 2005 Chemical Industry Press Beijing 213 214
129. P. Li, W.L. Zhu, and K.X. Chen Advances in the study of berberine and its derivatives Acta Pharm Sin 43 2008 773 787
130. Y. Zhou, S. Cao, Y. Wang, P. Xu, J. Yan, and W. Bin et al. Berberine metabolites could induce low density lipoprotein receptor up-regulation to exert lipid-lowering effects in human hepatoma cells Fitoterapia 92 2014 230 237
131. Y.H. Li, Y. Li, P. Yang, W.J. Kong, X.F. You, and G. Ren et al. Design, synthesis, and cholesterol-lowering efficacy for prodrugs of berberrubine Bioorg Med Chem 18 2010 6422 6428
132. C.M. Chen, and H.C. Chang Determination of berberine in plasma, urine and bile by high-performance liquid chromatography J Chromatogr B 665 1995 117 123
133. Guidance for determining subject matter eligibility of claims reciting or involving laws of nature, natural phenomena, & natural products http://www.uspto.gov/patent/patents-announcements/guidance-determining-subject-matter-eligibility-claims-reciting-or 2014
134. C. Harrison Patenting natural products just got harder Nat Biotechnol 32 2014 403 404
135. Xu JY, Wu XM, Yang JY, Ran J, Wang L, Wang ZX, et al. Preparation and application for oridonin derivatives. Chin. Pat. 200710133915.X;
136. Xu JY, Wang L, Zhang YH, Yao HQ, Li DH, Xu ST, et al. Preparation and application for oridonin derivatives as anticancer agents. Chin. Pat. 201010509348.5;
137. Xu JY, Wang L, Zhang YH, Yao HQ, Li DH, Xu ST, et al. Preparation and application for nitric oxide-releasing 14-O-oridonin derivatives. Chin. Pat. 201110178862.X.
138. Wu XM, Xu JY, Bi Y, Zhou JP, Zhang LY, Yuan ST, et al. Preparation and application for 23-hydroxybetulinic acid derivatives. Chin. Pat. 200610040277.2;
139. (b) Wu XM, Xu JY, Bi Y, Zhou JP, Zhang LY, Yuan ST, et al. Preparation and application for 23-hydroxybetulinic acid derivatives. Chin. Pat. 200810008418.1;
140. Wu XM, Xu JY, Zhu PQ, Yao HQ, Li Z, Sun F, et al. Preparation and application for 3,23,28- 23-hydroxybetulinic acid derivatives. Chin. Pat. 201010224698.7;
141. Wu XM, Xu JY, Zhu PQ, Yao HQ, Li Z, Sun F, et al. Preparation and application for heterocycycle-fused 23-hydroxybetulinic acid derivatives. Chin. Pat. 201010224690.0.
142. Xu JY, Bai RR, Jiang KT, Wu XM, Zhu Y, Xu D, et al. Preparation and application for nitric oxide-releasing isochroman-4-one derivatives as antihypertensive agents. Chin. Pat. 201210132644.7;
143. Xu JY, Bai RR, Liu J, Wu XM, Yang X, Hong W, et al. Preparation and application for isochroman-4-one bearing N-substituted as antihypertensive agents. Chin. Pat. 201210422187.5.
144. Shang J, Xu JY, Xu H, Wang RY, Chen JC, Duan WL, et al. Preparation for 13-β-elemene derivatives and their application in treatment of atherosclerosis. Chin. Pat. 201410376842.7;
145. Shang J, Xu JY, Xu H, Wang RY, Duan WL, Chen JC, et al. Preparation for 14-β-elemene derivatives and their application in treatment of atherosclerosis. Chin. Pat. 201410377535.0.